BR9916020A - Compostos e métodos para o tratamento e diagnóstico de infecção por chlamydia - Google Patents

Compostos e métodos para o tratamento e diagnóstico de infecção por chlamydia

Info

Publication number
BR9916020A
BR9916020A BR9916020-0A BR9916020A BR9916020A BR 9916020 A BR9916020 A BR 9916020A BR 9916020 A BR9916020 A BR 9916020A BR 9916020 A BR9916020 A BR 9916020A
Authority
BR
Brazil
Prior art keywords
compounds
polypeptides
diagnosis
treatment
methods
Prior art date
Application number
BR9916020-0A
Other languages
English (en)
Inventor
Peter Probst
Ajay Bhatia
Yasir A W Skeiky
Steven Fling
Shyian Jen
Erica Jean Stromberg
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/208,277 external-priority patent/US6166177A/en
Priority claimed from US09/288,594 external-priority patent/US6447779B1/en
Priority claimed from US09/410,568 external-priority patent/US6555115B1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of BR9916020A publication Critical patent/BR9916020A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSTOS E MéTODOS PARA O TRATAMENTO E DIAGNóSTICO DE INFECçãO POR CHLAMYDIA". Trata-se de compostos e métodos para o diagnóstico e tratamento de infecção por Chlamydia. Os compostos providos incluem polipeptídeos que contém pelo menos uma porção antigênica de um antígeno de Chlamydia e sequências de DNA codificando estes polipeptídeos. As composições farmacêuticas e vacinas compreendendo estes polipeptídeos ou sequências de DNA são também providas, junto com anticorpos dirigidos contra estes polipeptídeos. os kits diagnósticos contendo estes polipeptídeos ou sequências de DNA e um reagente de detecção apropriado podem ser usados para a detecção de infecção chlamidiana em pacientes e em amostras biológicas.
BR9916020-0A 1998-12-08 1999-12-08 Compostos e métodos para o tratamento e diagnóstico de infecção por chlamydia BR9916020A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/208,277 US6166177A (en) 1998-12-08 1998-12-08 Compounds and methods for the treatment and diagnosis of chlamydial infection
US09/288,594 US6447779B1 (en) 1998-12-08 1999-04-08 Compounds for the diagnosis of Chlamydial infection
US09/410,568 US6555115B1 (en) 1998-12-08 1999-10-01 Compounds and methods for treatment and diagnosis of chlamydial infection
US42657199A 1999-10-22 1999-10-22
PCT/US1999/029012 WO2000034483A2 (en) 1998-12-08 1999-12-08 Compounds and methods for treatment and diagnosis of chlamydial infection

Publications (1)

Publication Number Publication Date
BR9916020A true BR9916020A (pt) 2002-01-22

Family

ID=27498718

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916020-0A BR9916020A (pt) 1998-12-08 1999-12-08 Compostos e métodos para o tratamento e diagnóstico de infecção por chlamydia

Country Status (18)

Country Link
EP (5) EP1144642B1 (pt)
JP (2) JP2002531129A (pt)
KR (4) KR20070108263A (pt)
CN (1) CN100365120C (pt)
AT (1) ATE469222T1 (pt)
AU (2) AU769293B2 (pt)
BR (1) BR9916020A (pt)
CA (2) CA2354232A1 (pt)
DE (1) DE69942426D1 (pt)
ES (1) ES2346832T3 (pt)
HK (1) HK1044020B (pt)
HU (1) HUP0400719A3 (pt)
IL (5) IL143531A0 (pt)
MX (1) MXPA01005813A (pt)
NO (2) NO20012812L (pt)
NZ (1) NZ512246A (pt)
TR (1) TR200102500T2 (pt)
WO (1) WO2000034483A2 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
WO1999053948A1 (en) * 1998-04-20 1999-10-28 THE STATE OF OREGON, acting by and through THE STATE BOARD OF HIGHER EDUCATION, on behalf of OREGON STATE UNIVERSITY Chlamydia proteins and their uses
WO2000011181A1 (en) 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING INCLUSION MEMBRANE PROTEIN C OF $i(CHLAMYDIA)
AU5365999A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding pomp91a protein of (chlamydia)
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020094340A1 (en) 1998-12-01 2002-07-18 Andrew D. Murdin Chlamydia antigens and corresponding dna thereof
US6448234B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6555115B1 (en) 1998-12-08 2003-04-29 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6432916B1 (en) 1998-12-08 2002-08-13 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP1144642B1 (en) 1998-12-08 2010-05-26 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6447779B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds for the diagnosis of Chlamydial infection
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
ATE384738T1 (de) 1998-12-28 2008-02-15 Aventis Pasteur Chlamydia antigene, entsprechende dna fragmente und ihre verwendungen
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
EP2172214A3 (en) 1999-03-12 2011-03-16 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
ATE375391T1 (de) 1999-05-03 2007-10-15 Sanofi Pasteur Ltd Chlamydia-antigene und entsprechende dna- fragmente und deren verwendungen
WO2001021804A1 (en) 1999-09-20 2001-03-29 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
EP1240331B1 (en) 1999-12-22 2010-04-07 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6919187B2 (en) 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP2192128A3 (en) * 2000-04-21 2010-09-22 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
DE60125350T2 (de) 2000-05-08 2007-07-12 Sanofi Pasteur Ltd., Toronto Chlamydia-antigene, entsprechende dns-fragmente und ihre verwendungen
EP1297005B1 (en) * 2000-07-03 2009-08-26 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia pneumoniae
US7731980B2 (en) 2000-10-02 2010-06-08 Emergent Product Development Gaithersburg Inc. Chlamydia PMP proteins, gene sequences and uses thereof
US7537772B1 (en) * 2000-10-02 2009-05-26 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and the uses thereof
GB2378056A (en) * 2001-07-27 2003-01-29 William Dixon Electrical connection device
EP1463520B1 (en) 2001-12-12 2008-09-03 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
JP2004261017A (ja) 2003-02-27 2004-09-24 Arkray Inc クラミジア・トラコマティスの検出方法およびそのためのキット
WO2006104890A2 (en) * 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
EP1981905B1 (en) * 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
US20100172927A1 (en) * 2006-10-04 2010-07-08 Mark Alderson Vaccines Against Chlamydial Infection
WO2008156729A2 (en) * 2007-06-14 2008-12-24 Emergent Product Development Gaithersburg Inc. Vaccines against chlamydia infection
RU2011140508A (ru) 2009-03-06 2013-04-20 Новартис Аг Антигены хламидии
EP2557156B1 (en) 2010-03-23 2015-02-11 Wako Pure Chemical Industries, Ltd. Primer and probe for detecting chlamydia trachomatis, and method for detecting chlamydia trachomatis using same
AU2017294751B2 (en) * 2016-07-13 2023-10-05 Ohio State Innovation Foundation Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4429008B1 (en) 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
JPS59116229A (ja) 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US4673562A (en) 1983-08-19 1987-06-16 The Children's Medical Center Corporation Bisamide bisthiol compounds useful for making technetium radiodiagnostic renal agents
US4873088A (en) 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US4735792A (en) 1987-04-28 1988-04-05 The United States Of America As Represented By The United States Department Of Energy Radioiodinated maleimides and use as agents for radiolabeling antibodies
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0845537A1 (en) 1989-08-18 1998-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CZ282235B6 (cs) 1992-06-25 1997-06-11 Smithkline Beecham Biologicals (S.A.) Očkovací prostředek, jeho použití k výrobě vakcíny, způsob léčby patogenních infekcí tímto prostředkem a způsob jeho výroby
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
US5840297A (en) * 1993-03-19 1998-11-24 Johns Hopkins University Vaccine comprising anti-idiotypic antibody to chlamydia GLXA and process
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE328890T1 (de) 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
CN100365017C (zh) * 1994-09-20 2008-01-30 日立化成工业株式会社 肺炎衣原体抗原多肽
WO1996016178A1 (en) * 1994-11-17 1996-05-30 Maxim Pharmaceuticals, Inc. Immunogens for stimulating mucosal immunity
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
WO1996038591A1 (en) 1995-06-02 1996-12-05 Incyte Pharmaceuticals, Inc. IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES
JP2002515734A (ja) 1996-01-02 2002-05-28 カイロン コーポレイション 遺伝子改変された樹状細胞により媒介される免疫刺激
AU723235B2 (en) * 1996-07-12 2000-08-24 University Of Manitoba DNA immunization against Chlaymdia infection
US6464979B1 (en) * 1996-09-12 2002-10-15 Aventis Pasteur Limited Chlamydial vaccines and methods of preparation thereof
WO2001023604A2 (en) * 1999-09-28 2001-04-05 Infectio Diagnostic (I.D.I.) Inc. Highly conserved genes and their use to generate probes and primers for detection of microorganisms
EP1854885B9 (en) 1997-11-21 2011-03-16 Merck Serono Biodevelopment Chlamydia pneumoniae outer membrane polypeptide, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
AU754264B2 (en) * 1997-11-28 2002-11-07 Genset S.A. Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
AU5297399A (en) * 1998-08-20 2000-03-14 Aventis Pasteur Limited (chlamydia) antigens and corresponding dna fragments and uses thereof
AU1722300A (en) 1998-11-12 2000-05-29 Regents Of The University Of California, The Chlamydia pneumoniae genome sequence
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
EP1144642B1 (en) 1998-12-08 2010-05-26 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) * 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
ATE375391T1 (de) 1999-05-03 2007-10-15 Sanofi Pasteur Ltd Chlamydia-antigene und entsprechende dna- fragmente und deren verwendungen
WO2001021804A1 (en) 1999-09-20 2001-03-29 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
EP1240331B1 (en) 1999-12-22 2010-04-07 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
EP2192128A3 (en) 2000-04-21 2010-09-22 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
DE60125350T2 (de) 2000-05-08 2007-07-12 Sanofi Pasteur Ltd., Toronto Chlamydia-antigene, entsprechende dns-fragmente und ihre verwendungen
EP1297005B1 (en) 2000-07-03 2009-08-26 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia pneumoniae
US9103184B2 (en) 2013-03-08 2015-08-11 Tejas Research & Engineering, Llc Inflow control valve
US10358498B2 (en) 2014-08-11 2019-07-23 Daiichi Sankyo Europe Gmbh Human anti-FGFR4 antibody

Also Published As

Publication number Publication date
IL209115A0 (en) 2011-01-31
EP1144642B1 (en) 2010-05-26
KR20100132086A (ko) 2010-12-16
IL209116A0 (en) 2011-01-31
NO20012812L (no) 2001-08-02
WO2000034483A9 (en) 2001-07-05
CN1333832A (zh) 2002-01-30
PL363147A1 (en) 2004-11-15
NO20012812D0 (no) 2001-06-07
DE69942426D1 (de) 2010-07-08
EP2277893A2 (en) 2011-01-26
EP2223935A3 (en) 2010-11-24
HUP0400719A3 (en) 2010-08-30
WO2000034483A3 (en) 2001-11-01
EP2277892A3 (en) 2011-04-27
JP2011036258A (ja) 2011-02-24
EP2223935A2 (en) 2010-09-01
AU2004201702B2 (en) 2007-07-05
HK1044020A1 (en) 2002-10-04
KR20070108263A (ko) 2007-11-08
HK1044020B (zh) 2008-10-31
TR200102500T2 (tr) 2002-03-21
EP2277892A2 (en) 2011-01-26
IL209114A0 (en) 2011-01-31
EP1144642A2 (en) 2001-10-17
AU1935800A (en) 2000-06-26
CA2746535A1 (en) 2000-06-15
EP2218733A1 (en) 2010-08-18
HUP0400719A2 (hu) 2004-07-28
MXPA01005813A (es) 2002-05-06
NO20101293L (no) 2001-08-02
KR20010101152A (ko) 2001-11-14
IL143531A0 (en) 2002-04-21
AU769293B2 (en) 2004-01-22
KR100829407B1 (ko) 2008-05-15
ES2346832T3 (es) 2010-10-20
CN100365120C (zh) 2008-01-30
CA2354232A1 (en) 2000-06-15
NZ512246A (en) 2003-12-19
AU2004201702A1 (en) 2004-05-20
WO2000034483A2 (en) 2000-06-15
IL209113A0 (en) 2011-01-31
EP2277893A3 (en) 2011-03-30
JP2002531129A (ja) 2002-09-24
KR20090088972A (ko) 2009-08-20
ATE469222T1 (de) 2010-06-15

Similar Documents

Publication Publication Date Title
BR9916020A (pt) Compostos e métodos para o tratamento e diagnóstico de infecção por chlamydia
BR0016066A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
BR0112602A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
AU2001255596A1 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
WO1998042740A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
WO2003086308A3 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
WO2000000615A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
EP1297147B8 (en) Compositions for the diagnosis and treatment of herpes simplex virus infection
EP0834567A3 (en) Compounds and methods for the diagnosis and treatment of Babesia microti infection
WO2001085949A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
WO2003020108A3 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
WO2002053016A3 (en) Compounds and methods for the diagnosis and treatment of babesia infection
WO2001085947A3 (en) Compounds and methods for the diagnosis and treatment of babesia microti infection

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements